BGB-A3055 / BeOne Medicines - LARVOL DELTA

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=263 | Active, not recruiting | Sponsor: BeiGene | Recruiting ➔ Active, not recruiting

Enrollment closed • IO biomarker • Oncology • Solid Tumor • CCR8 • PD-L1

BGB-A3055, an afucosylated anti-CCR8 antibody, preferentially depletes intratumoral regulatory T cells and inhibits tumor growth in preclinical models (AACR 2025) - P1 | "BGB-3055 is a novel fully humanized afucosylated antibody that has high binding affinity to hCCR8, strong CCL1-CCR8 blocking capacity and potent ADCC effect. BGB-A3055 demonstrated strong anti-tumor activity as single agent or in combination with PD-1 antibody. A Ph1 study evaluating BGB-A3055 alone and in combination with Tislelizumab in participants with solid tumor is ongoing (NCT05935098)."

Preclinical • Oncology • Solid Tumor • CCR8

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=263 | Recruiting | Sponsor: BeiGene | Trial completion date: Feb 2025 ➔ Mar 2027 | Trial primary completion date: Feb 2025 ➔ Mar 2027

Trial completion date • Trial primary completion date • Oncology • Solid Tumor • CCR8

Simcere Pharmaceuticals' Phase III study of innovative anti-influenza drug was successful; Junshi Biologics' first-quarter revenue was 380 million yuan [Google translation] (163.com) - "On April 29, according to the CDE official website, Hengrui Medicine’s injection SHR-9839 was approved for clinical use and is planned to be combined with SHR-A2009, or SHR-A1921, or ametinib, or combined with chemotherapy to treat advanced solid tumors...according to the CDE official website, Yangli Pharmaceutical VB15010 tablets were approved for clinical use and plans to conduct research on the treatment of advanced solid tumors....according to the CDE official website, BeiGene’s BGB-A3055 for injection was approved for clinical use and plans to conduct research on the treatment of advanced or metastatic solid tumors."

New trial • Oncology • Solid Tumor

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=318 | Recruiting | Sponsor: BeiGene

Combination therapy • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • CCR8

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=318 | Recruiting | Sponsor: BeiGene | Phase classification: P1a/1b ➔ P1

Combination therapy • Metastases • Phase classification • Oncology • Solid Tumor • CCR8

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1a/1b | N=318 | Recruiting | Sponsor: BeiGene | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • IO biomarker • Metastases • Oncology • Solid Tumor • CCR8 • PD-L1

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1a/1b | N=318 | Not yet recruiting | Sponsor: BeiGene

Combination therapy • IO biomarker • Metastases • New P1 trial • Oncology • Solid Tumor • CCR8 • PD-L1